Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
  • Home
  • About Us
    • Management Team
    • Board of Directors
  • Products in Development
    • TO-2061
  • Investors
    • Press Releases
    • Events & Presentations
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Historic Stock Lookup
    • Analysts
    • Shareholder Tools
      • Shareholder Briefcase
      • Email Alerts
  • Careers
  • Contact
 

For more information, please click here »

News & Events

    Wednesday, December 21, 2011

    Transcept Pharmaceuticals Receives $10 Million Milestone Payment from Purdue for Listing of Intermezzo Formulation Patents in FDA Orange Book

    Thursday, December 8, 2011

    Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011

    Wednesday, November 30, 2011

    Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of Option to Commercialize Intermezzo® in the United States

    Wednesday, November 30, 2011

    Transcept Pharmaceuticals Announces Purdue's Exercise of Option to Commercialize Intermezzo® in the United States

In Development

Transcept is developing TO-2061, a low dose form of ondansetron, as an adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication.

Click here for more information about TO-2061

Copyright © 2012  |  
Sitemap  |  Contact Us